Aligos Therapeutics (ALGS) Retained Earnings (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Retained Earnings for 5 consecutive years, with -$642.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 3.91% year-over-year to -$642.2 million, compared with a TTM value of -$642.2 million through Dec 2025, down 3.91%, and an annual FY2025 reading of -$642.2 million, down 3.91% over the prior year.
- Retained Earnings was -$642.2 million for Q4 2025 at Aligos Therapeutics, down from -$622.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $497000.0 in Q2 2023 and bottomed at -$642.2 million in Q4 2025.
- Average Retained Earnings over 5 years is -$310.5 million, with a median of -$410.6 million recorded in 2022.
- Peak annual rise in Retained Earnings hit 894.0% in 2023, while the deepest fall reached 288719.5% in 2023.
- Year by year, Retained Earnings stood at $452000.0 in 2021, then plummeted by 88396.46% to -$399.1 million in 2022, then dropped by 21.97% to -$486.8 million in 2023, then dropped by 26.95% to -$618.0 million in 2024, then decreased by 3.91% to -$642.2 million in 2025.
- Business Quant data shows Retained Earnings for ALGS at -$642.2 million in Q4 2025, -$622.3 million in Q3 2025, and -$590.8 million in Q2 2025.